Haemato
Stock
Stock
ISIN: DE000A289VV1
Ticker: HAEK
DE000A289VV1
HAEK
Price
Price
CHART BY
Frequently asked questions
What is Haemato's market capitalization?
The market capitalization of Haemato is $61.43M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Haemato?
Haemato's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.175. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Haemato's stock?
Currently, 1 analysts cover Haemato's stock, with a consensus target price of $38.91. Analyst ratings provide insights into the stock's expected performance.
What is Haemato's revenue over the trailing twelve months?
Over the trailing twelve months, Haemato reported a revenue of $307.49M.
What is the EBITDA for Haemato?
Haemato's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $12.17M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Haemato?
Haemato has a free cash flow of $13.01M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of Haemato's shares?
The free float of Haemato is 1.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $61.43M
- EPS (TTM)
- $2.175
- Free Float
- 1.65M
- Revenue (TTM)
- $307.49M
- EBITDA (TTM)
- $12.17M
- Free Cashflow (TTM)
- $13.01M
Pricing
- 1D span
- $12.11$12.31
- 52W span
- $10.51$17.37
Analyst Ratings
The price target is $38.91 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Haemato AG engages in the pharmaceutical industry. It focuses on growth markets of patent-free, and patented medicinal products in the insurance-financed market. Its portfolio include therapies for cancer, HIV, rheumatology, and other chronic diseases, and products for the privately financed market for aesthetic treatments. It operates through the Lifestyle and Aesthetics, and Specially Pharma segments. The company was founded on May 10, 1993 and is headquartered in Schönefeld, Germany.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- DE000A289VV1
- Primary Ticker
- HAEK
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet